By 2030, it is anticipated that the South Africa infectious disease therapeutics market will reach a value of $1203 Mn from $779.2 Mn in 2022, growing at a CAGR of 5.6% during 2022-2030. The Infectious Disease Therapeutics in South Africa is dominated by a few domestic pharmaceutical companies such as Biovac, Adcock Ingram and Aspen Pharmacare. The Infectious Disease Therapeutics market in South Africa is segmented into different therapeutic areas and different diseases type. The major factors affecting the South African infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, COVID-19, and the amount of healthcare funding for infectious diseases treatment in various areas of South Africa.
By 2030, it is anticipated that the South Africa infectious disease therapeutics market will reach a value of $1203 Mn from $779.2 Mn in 2022, growing at a CAGR of 5.6% during 2022-2030.
South Africa is an upper-middle-income, developing country located at the southern tip of the African continent. According to the World Factbook, South Africa is vulnerable to the following infectious illnesses. Bacterial diarrhoea, hepatitis A and E, and typhoid fever are all examples of food or waterborne illnesses. Infectious disorders caused by water contact, such as schistosomiasis, are frequent in South Africa.
Malaria is widespread in many regions of the country, notably in the northern provinces, and attempts to curb the disease's spread are ongoing, including the provision of insecticide-treated bed nets and other preventive measures. South Africa's government spends 8.6% of its GDP on healthcare.

Market Growth Drivers Analysis
South Africa's government has been working to strengthen the country's healthcare system and increase access to healthcare for all inhabitants, which is projected to boost the infectious disease therapeutics market even further. South Africa is a regional economic and political force with a huge, young population. These aspects could boost the South African infectious disease therapeutics market.
Market Restraints
In South Africa, the cost of infectious disease medicines can be relatively high, limiting the affordability and accessibility of these drugs for many patients. South Africa has one of the world's highest rates of HIV/AIDS prevalence, which can divert resources away from other infectious disease therapies and limit the market potential for new medications. Poverty, widening disparities, significant unemployment (particularly among young people), and sources of social danger are all problems in South Africa (crime, strikes and demonstrations). These factors may deter new entrants into the South African infectious disease therapeutics market.
Key Players
December 2022: Aspen Pharmacare, Africa's largest pharmaceutical firm and a global specialised and branded pharmaceutical company, has announced an additional $15.2 Mn investment in its main pharmaceutical manufacturing location in Gqeberha. The news follows Aspen's previous investment of more than $243.6 Mn in this world-class manufacturing facility in the Eastern Cape. The project began in November 2021, and the investment will provide increased capacity for filling and finishing a variety of sterile items, including vaccinations.
The South African Health Products Regulatory Authority (SAHPRA) and the National Department of Health oversee the regulation and reimbursement of infectious disease therapies in South Africa (NDoH). The National Health Insurance (NHI) programme governs the payment procedure for infectious disease treatments in South Africa.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the South Africa infectious disease therapeutics market will reach a value of $1203 Mn from $779.2 Mn in 2022, growing at a CAGR of 5.6% during 2022-2030.
In South Africa, the regulation and reimbursement of infectious disease therapeutics are overseen by several entities, including the South African Health Products Regulatory Authority (SAHPRA) and the National Department of Health (NDoH).
The Infectious Disease Therapeutics in South Africa is dominated by a few domestic pharmaceutical companies such as Biovac, Adcock Ingram and Aspen Pharmacare.